Attention-Deficit/Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUD) frequently co-occur, resulting in complex clinical presentations and significant challenges in diagnosis, treatment, and long-term management. This research paper synthesizes insights from Dartmouth Grand Rounds, focusing on the epidemiology, shared neurobiological mechanisms, diagnostic challenges, and integrated treatment strategies for ADHD and SUD. Evidence-based pharmacological approaches, psychosocial interventions, and harm reduction models are examined, with attention to the balance between treating ADHD symptoms and mitigating substance misuse risks. Recommendations for individualized, multidisciplinary care are discussed to improve functional outcomes and quality of life in affected individuals.

KeyWords:

1. Introduction

ADHD is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity, often continuing into adulthood. SUD encompasses the maladaptive use of substances, leading to clinically significant impairment or distress. The co-occurrence of ADHD and SUD is notably high, with prevalence estimates indicating that approximately 15–25% of adults with SUD also meet criteria for ADHD. This dual diagnosis complicates both conditions, with ADHD potentially increasing vulnerability to substance misuse and SUD exacerbating cognitive and behavioral symptoms.

International License (CC BY SA) (http://creativecommons.org/licenses/by-sa/4.0/) 

How to Cite:

P. Pertama et al., "Judul Dalam Bahasa Indonesia-Sub-judul jika diperlukan max 12 kata", JIKO (JURNAL INFORMATIKA DAN 

KOMPUTER), Volume: 8, No.1, Pages 15–22, Februari 2024, doi: 10.26798/jiko.v8i1.xxx.

16 PenulisPertamaetal.

2. Epidemiology and Risk Factors

Research shows that early-onset ADHD is a strong predictor of later substance misuse. Genetic predisposition, impulsivity, and deficits in executive functioning create a pathway toward self medication with substances such as alcohol, nicotine, cannabis, or stimulants. Environmental stressors, adverse childhood experiences, and lack of early intervention further amplify the risk. The Dartmouth presentation highlighted that untreated ADHD often leads to academic underachievement, poor self-regulation, and social difficulties, all of which increase susceptibility to SUD.

3.Shared Neurobiology

ADHD and SUD share overlapping neurobiological pathways involving dopaminergic and noradrenergic systems. Dysregulation in the prefrontal cortex, striatum, and reward circuitry contributes to impaired impulse control, heightened reward sensitivity, and diminished executive functioning. Chronic substance use can further dysregulate these systems, creating a bidirectional worsening of both disorders.

4. Diagnostic Challenges

Accurate diagnosis is complicated by symptom overlap. Substance use can mimic ADHD features, while ADHD symptoms may be misattributed to withdrawal or intoxication effects. The Dartmouth approach emphasizes comprehensive assessment, including collateral history, structured diagnostic interviews, ADHD rating scales, and careful consideration of the temporal relationship between symptom onset and substance use patterns.

5. Treatment Approaches

5.1 ADHD Management

Pharmacotherapy is central to ADHD treatment. Evidence supports the cautious use of long acting stimulants (e.g., methylphenidate ER, lisdexamfetamine) in patients with concurrent SUD, as these formulations have lower abuse potential. Non-stimulant options, such as atomoxetine, guanfacine XR, and bupropion, may be preferable for individuals with high misuse risk. The Dartmouth protocol recommends close monitoring, pill counts, and prescription tracking to reduce diversion risk.

5.2 SUD Management

SUD treatment in this population involves medication-assisted treatment (MAT) for specific substances—such as buprenorphine or methadone for opioid use disorder, and naltrexone for alcohol use disorder—combined with behavioral therapies. Contingency management, motivational interviewing, and cognitive-behavioral therapy (CBT) are emphasized for promoting abstinence and relapse prevention.

5.3 Psychosocial Interventions

Integrated psychosocial support addresses both ADHD-related functional impairments and substance use behaviors. Strategies include skills training for organization and time management, peer support groups, vocational rehabilitation, and family psychoeducation. Addressing comorbid mood and anxiety disorders is also crucial for long-term stability.

6. Integrated Care Model

The Dartmouth Grand Rounds underscored that siloed treatment approaches fail to address the complex interplay of ADHD and SUD. Instead, integrated care—where a single team manages both disorders simultaneously—has shown better retention, adherence, and recovery outcomes. Regular interdisciplinary meetings, shared treatment plans, and coordinated medication management are essential features of this model.

7. Psychosocial Development Considerations

Individuals with ADHD and SUD often experience developmental delays in emotional regulation, social skills, and occupational functioning. Early intervention in adolescence can mitigate these deficits. Interventions that promote self-efficacy, structured routines, and positive social engagement foster resilience and support sustained recovery.

8. Recommendations and Future Directions

Long-Acting Medications: Prioritize extended-release formulations to minimize abuse potential.

Integrated Behavioral Care: Use evidence-based psychosocial therapies tailored to dual-diagnosis populations.

Training for Providers: Equip clinicians with skills to navigate dual treatment complexities.

Research Expansion: Conduct longitudinal studies to assess outcomes of integrated pharmacological and behavioral approaches.

Early Screening: Implement universal ADHD screening in addiction treatment settings.

9. Conclusion

The co-occurrence of ADHD and SUD represents a multifaceted clinical challenge requiring precise diagnosis, balanced pharmacological intervention, and robust psychosocial support. Insights from the Dartmouth Grand Rounds reinforce the value of integrated care models that simultaneously address cognitive symptoms, addictive behaviors, and functional impairments. By tailoring treatment to the unique neurobiological and psychosocial needs of these individuals, healthcare providers can improve recovery trajectories and quality of life.

References

1. Dartmouth-Hitchcock Medical Center. (2024). ADHD and Substance Use Disorders [Grand Rounds Video]. YouTube.

2. Wilens, T.E., & Morrison, N.R. (2012). The intersection of attention-deficit/hyperactivity disorder and substance abuse. Current Opinion in Psychiatry, 25(4), 258–264.

3. Kessler, R.C., et al. (2006). The prevalence and correlates of adult ADHD in the United States. American Journal of Psychiatry, 163(4), 716–723.